Salute e Benessere

Endometriosis Treatment Market to Surge to US$ 3.1 Billion by 2034: Innovations…

Hormone therapies such as GnRH agonists and antagonists, aromatase inhibitors, and other hormonal medicines, are crucial in controlling endometriosis-related pain. Newer medications, such as GnRH antagonists like Elagolix and Letrozole, have showed promise, especially in terms of pain relief and fertility outcomes. Hormone therapies such as GnRH agonists and antagonists, aromatase inhibitors, and other hormonal medicines, are crucial in controlling endometriosis-related pain. Newer…
PR Newswire
26/07/2024

Cell Isolation/Separation Market worth $8.4 billion by 2029 driven by Growing…

Browse in-depth TOC on "Cell Isolation Market" Browse in-depth TOC on "Cell Isolation Market" 456 - Tables 62 - Figures 475 - Pages DANAHER CORPORATION (US): Leader in Cell Separation and Analysis Danaher Corporation emerged as a leader in the cell separation and analysis market due to its advanced technology, including greater automation and precise instrumentation. The company excels in improving cell separation reliability and efficiency, enabling researchers to...
PR Newswire
26/07/2024

Specialty Enzymes Market to Surpass USD 10.4 Billion by 2034, Growing at a 6.4%…

Enzymes are proteins that selectively catalyze chemical reactions, playing crucial roles in essential life processes such as digestion, respiration, and metabolism. The specialty enzymes market is expanding due to the rising demand for effective biocatalysts in pharmaceuticals and diagnostics, which drives innovation. Biotechnology and genetic engineering advancements have enabled the development of more efficient and specific enzymes, broadening their application scope. Enzymes are proteins...
PR Newswire
26/07/2024

Home Bedding Market to reach 145.95 Bn at a CAGR of 6.06 percent by 2030- Says…

Key Offerings Key Offerings Rise of Sleep-Enhancing Technology to Create Growth Opportunities Smart mattresses and bedding systems are now equipped with built-in sensors that monitor sleep patterns, heart rate, and body movements providing users with customized recommendations and insights. For instance, the Sleep Number 360 smart bed utilizes SleepIQ technology to make real-time adjustments and track sleep, benefiting a user base of over 12 million people. Smart pillows such as the...
PR Newswire
26/07/2024

Pharmerging Market Set to Hit USD 7.1 Billion by 2034, Driven by Surge in Demand…

The pharmerging market, comprises of nations such as Brazil, Russia, India, and China (BRIC) and other rapidly emerging economies, these have dynamic environment with multiple opportunities and challenges. These countries account for 40% of the world's population, with a growing middle class and an increasing prevalence of chronic diseases, driving demand for pharmaceuticals. The rapid growth in healthcare expenditures in these markets contrasts sharply with the relatively sluggish growth in G7…
PR Newswire
26/07/2024

CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as…

Dr. Jason Yang, CEO, President of R&D and Executive Director of the Board at CStone, said, "We are extremely excited by today's announcement, which represents a major milestone in CStone's journey towards becoming a leading global company dedicated to eradicating cancer. Sugemalimab has not only become CStone's first independently-developed product to receive overseas marketing authorization but it is also the world's first anti-PD-L1 mAb to receive regulatory approval in Europe in…
PR Newswire
26/07/2024

Eisai will seek re-examination of CHMP opinion för lecanemab

A formal request for re-examination allows the applicant a 60-day period to provide the CHMP with the grounds for the re-examination request. The CHMP, led by new rapporteurs, will have 60 days to respond. A formal request for re-examination allows the applicant a 60-day period to provide the CHMP with the grounds for the re-examination request. The CHMP, led by new rapporteurs, will have 60 days to respond. Lecanemab is already approved inthe United States,Japan,China,South Korea...
PR Newswire
26/07/2024

GENFIT: Positive Opinion from EMA Committee for Ipsen's Iqirvo® (elafibranor) in…

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024-GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) for Ipsen's Iqirvo® (elafibranor) for the treatment of Primary Biliary Cholangitis...
Nasdaq GlobeNewswire
26/07/2024

Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the…

TOKYO and CAMBRIDGE, Mass., July26, 2024(GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Marketing Authorization Approval (MAA) for the humanized anti-soluble aggregated...
Nasdaq GlobeNewswire
26/07/2024

CHMP has adopted a negative opinion on lecanemab for the EU

Eisai is responsible for the clinical development, applications for market approval and commercialization of lecanemab for Alzheimer's disease. BioArctic has the right to commercialize lecanemab in the Nordic region, pending European approval, and currently Eisai and BioArctic are preparing for a joint commercialization in the region. Eisai is responsible for the clinical development, applications for market approval and commercialization of lecanemab for Alzheimer's disease. BioArctic has…
PR Newswire
26/07/2024

Medical Oxygen Concentrators Market to Reach USD 7.1 Billion by 2034, Growing at…

The medical oxygen concentrator is one form of medical equipment used to provide oxygen to people with breathing-related illnesses. The respiratory mechanisms and metabolism of living things depend heavily on oxygen. An oxygen concentrator is frequently necessary for those with low blood oxygen concentrations to restore oxygen levels. The medical oxygen concentrator is one form of medical equipment used to provide oxygen to people with breathing-related illnesses. The respiratory mechanisms…
PR Newswire
26/07/2024

Piramal Pharma Limited Announces Consolidated Results for Q1FY25

Key Highlights for Q1FY25 Key Highlights for Q1FY25 Nandini Piramal, Chairperson, Piramal Pharma Limited,said, " We have had a good start to the financial year with a steady all-round performance. We delivered a healthy revenue growth accompanied by over 170bps YoY expansion in EBIDTA margin driven by favorable revenue mix and cost optimization initiatives. Our CDMO business continues to witness sustained order inflows, especially for on-patent commercial manufacturing. We are also...
PR Newswire
26/07/2024

Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary…

Ipsen receives CHMP positive opinions for Iqirvo ®(elafibranor) in Primary Biliary Cholangitis and Kayfanda ®(odevixibat) in Alagille Syndrome, two rare cholestatic liver diseasesCHMP positive opinion for Iqirvo ®(elafibranor) recommended for the treatment of primary biliary cholangitis, following FDA approval in June 2024CHMP positive opinion for Kayfanda ®(odevixibat) recommended for cholestatic pruritus in patients with Alagille syndrome...
Nasdaq GlobeNewswire
26/07/2024

Coagulation Testing Market to Reach USD 6.5 Billion by 2034: Surgical…

As the global population ages, there is a growing need for coagulation testing among the elderly population, who are at higher risk of thrombotic events and coagulation disorders, driving market expansion. Rapid economic development and improved healthcare infrastructure in emerging markets lead to greater accessibility to coagulation testing, fostering market growth and catering to previously underserved populations. As the global population ages, there is a growing need for coagulation...
PR Newswire
26/07/2024

Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary…

The treatment groups were relatively well-balanced with no clinically relevant differences between the groups observed at baseline. The result is particularly encouraging as over 40% of the trial population was on dual therapy, ie was receiving UDCA (ursodeoxycholic acid) and either Ocaliva (obeticholic acid) or Bezafibrate (PPAR agonist) as base therapy and 13% were receiving all three therapies during the study, reflecting setanaxib having clinically relevant incremental benefit beyond…
PR Newswire
26/07/2024

S&P Global Ratings Reaffirms MAXIMA GRUPĖ, UAB BB+ Credit Rating with stable…

On July 25, 2024, following the review of group's operations and financial results, the international credit rating agency, has reaffirmed MAXIMA GRUPĖ's long-term issuer credit rating at BB+ with a stable outlook. S&P Global Ratings report highlights the group's revenue growth, successful expansion in Poland and Bulgaria, efficiently managed costs and stable cash flow generation.“We are pleased that S&P Global Ratings has recognized our strong performance in 2023, which exceeded...
Nasdaq GlobeNewswire
26/07/2024

Bavarian Nordic Receives Positive CHMP Opinion for Including Mpox Real-world…

Real-world data demonstrating vaccine effectiveness against mpox of up to 90% after two MVA-BN doses and a significant reduction of the risk of mpox-related hospitalizationsCOPENHAGEN, Denmark, July 26, 2024– Bavarian Nordic A/S (OMX: BAVA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a type II variation for IMVANEX ®(MVA-BN) smallpox and mpox vaccine, including real-world...
Nasdaq GlobeNewswire
26/07/2024

XRP Healthcare Secures Major Media Partnership with Global Exhibition Titans

Kain Roomes, CEO at XRP Healthcare said: Kain Roomes, CEO at XRP Healthcare said: "Our partnership with ACE Group and Genesis Global Exhibitions will significantly enhance the visibility of XRP Healthcare Magazine. This increased exposure will help us connect with industry leaders and innovators, driving the value and impact of XRP Healthcare." ACE Group has solidified its reputation as one ofIndia'sleading exhibition organizers, with over eight years of experience in the industry...
PR Newswire
26/07/2024

Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer

“After an extensive search, we are delighted to have Leone Patterson join us at this exciting time as we plan for our next stage of growth and development at Zymeworks,” said Kenneth Galbraith, Chair and CEO of Zymeworks. “She brings more than 20 years of public company biotech experience with a proven track record of guiding strategy, finance, operations, and governance through multiple phases of growth, planning and executing successful financial strategies. Ms. Patterson has the...
Nasdaq GlobeNewswire
25/07/2024

FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to…

ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transplantation (HSCT) or relapse afterFDA ODD and RPDD designations for UCART22 marks an important step towards developing allogeneic CAR T products that would be readily available for all patients...
Nasdaq GlobeNewswire
25/07/2024

Inventiva secures a new patent in Japan, expanding the IP protection of its lead…

Japanese Patent Office approved Inventiva's patent application relating to the use of lanifibranor for the treatment of cirrhosis. 1 This patent strengthens Inventiva's intellectual property with respect to lanifibranor in Japan for the indication cirrhosis, including cirrhosis due to MASH/NASH.Daix (France), Long Island City (New York, United States), July 25, 2024– Inventiva (Euronext Paris and Nasdaq: IVA) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical...
Nasdaq GlobeNewswire
25/07/2024

Immunovia presents data from discovery study at 2024 PancreasFest medical…

Results presented at PancreasFest reflect a detailed scientific presentation of the initial positive data the company shared in a 7 November 2023 press release. Results presented at PancreasFest reflect a detailed scientific presentation of the initial positive data the company shared in a7 November 2023press release. The discovery study, the most comprehensive pancreatic cancer proteomics study done to date, identified 15 promising protein biomarkers that were shown to strongly...
PR Newswire
25/07/2024

Oxurion Share Consolidation

Oxurion Share ConsolidationLeuven, BELGIUM – July 25, 2024 – 06:00 PM CET Oxurion NV(Euronext Brussels: OXUR) (theCompany ), a biopharmaceutical company based in Leuven, announced today that its Board of Directors, authorized by the General Meeting of July 24, 2024, will proceed with a consolidation of all existing shares. This consolidation will be carried out at a ratio of one (1) new share for ten thousand (10,000) existing shares.This share consolidation is a strategic step to...
Nasdaq GlobeNewswire
25/07/2024

EssilorLuxottica: Q2/H1 2024 Results - Sound revenue growth, margins expanding…

Q2/H1 2024 ResultsSound revenue growth, margins expanding,two acquisitions in line with strategy Revenue growing by 5.2% in Q2 at constant exchange rates 1, +5.3% in H1EMEA as the driving region, North America keeping the pace of Q1Stellest in China and Ray-Ban Meta wearables continuing to grow exponentiallyAdjusted 2operating profit margin at 18.8%, up 50bps at constant exchange rates 1 Strong free cash flow 5generation, at Euro 971 million in...
Nasdaq GlobeNewswire
25/07/2024
Altri  Comunicati